Challenging Perceptions About Oncology Product Pricing in Breast and Colorectal Cancer

Pharmaceutical Medicine

Volumn 30, Issue 6, 2016, Pages 321-326

  Barron, Anthony ^a   Wilsdon, Tim ^a  

^a CHARLES RIVER ASSOCIATES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; ATTITUDE TO HEALTH; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE COST; HEALTH CARE QUALITY; HUMAN; MONEY; OVERALL SURVIVAL; PRIORITY JOURNAL;

EID: 84995581840     PISSN: 11782595     EISSN: 11791993     Source Type: Journal    
DOI: 10.1007/s40290-016-0167-1     Document Type: Article

References (24)

1. Danzon PM, Taylor E. Drug pricing and value in oncology. Oncologist. 2010;15(Suppl 1):24–31.
2. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013;121(22):4439–42.
3. Ghinea N, Kerridge I, Lipworth W. If we don’t talk about value, cancer drugs will become terminal for health systems. The Conversation. 2015 [online]. Available from: http://theconversation.com/if-we-dont-talk-about-value-cancer-drugs-will-become-terminal-for-health-systems-44072. Accessed 20 Oct 2016.
4. Kelly RJ, Smith TJ. Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care. Lancet Oncol. 2014;15(3):e112–8.
5. Cavalli F. An appeal to world leaders: stop cancer now. Lancet. 2013;381(9865):425–6.
6. Godman B, Malmström RE, Diogene E, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert Rev Clin Pharmacol. 2015;8(1):77–94.
7. Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst. 2009;101(15):1044–8.
8. Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs in the United States: Justum Pretium—the just price. J Clin Oncol. 2013;31(28):3600–4.
9. Mailankody S, Prasad V. Five years of cancer drug approvals: innovation, efficacy, and costs. JAMA Oncol. 2015;1(4):539–40.
10. Howard DH, Bach PB, Berndt ER, Conti RM. Pricing in the market for anticancer drugs. J Econ Perspect. 2015;29(1):139–62.
11. Ramsey SD. How state and federal policies as well as advances in genome science contribute to the high cost of cancer drugs. Health Aff. 2015;34(4):571–5.
12. Barrett A, Roques T, Small M, Smith RD. How much will herceptin really cost? BMJ. 2006;333(7578):1118–20.
13. Haycox A. Why cancer? Pharmacoeconomics. 2016;34:625–7.
14. Santa-Maria CA, Gradishar WJ. Changing treatment paradigms in metastatic breast cancer: lessons learned. JAMA Oncol. 2015;1(4):528–34.
15. Pilon D, Queener M, Lefebvre P, Ellis LA. Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer. J Med Econ. 2016;19(8):777–84.
16. Whalen J, Chang J, Ozer-Stillman I, Ambavane A, Ngai C. The cost of survival gain in metastatic colorectal cancer (mCRC) in Spain [abstract P-213]. Ann Oncol. 2015;26(Suppl. 4):iv62–iv62.
17. Whalen J, Chang J, Ozer-Stillman I, Ambavane A, Ngai C. The cost of survival gain in metastatic colorectal cancer (mCRC) in France [abstract P-212]. Ann Oncol. 2015;26(Suppl. 4):iv61–2.
18. De Angelis R, Sant M, Coleman MP, Francisci S. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study. Lancet Oncol. 2014;15(1):23–34. doi:10.1016/S1470-2045(13)70546-1.
19. Independent Cancer Taskforce. Achieving world-class cancer outcomes: a strategy for England 2015–2020, a report of the Independent Cancer Taskforce [online]. Available from: http://www.cancerresearchuk.org/sites/default/files/achieving_world-class_cancer_outcomes_-_a_strategy_for_england_2015-2020.pdf. Accessed 27 Sep 2016.
20. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010;10(5):317–27.
21. Lakdawalla D, Shafrin J, Lucarelli C, Nicholson S, Khan ZM, Philipson TJ. Quality-adjusted cost of care: a meaningful way to measure growth in innovation cost versus the value of health gains. Health Aff. 2015;34(4):555–61.
22. IMS Institute for Healthcare Informatic. Developments in cancer treatments, market dynamics, patient access and value: global oncology trend report 2015. Available from: http://www.imshealth.com/en/thought-leadership/quintilesims-institute/reports/global-oncology-trend-2015#ims-form.
23. Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 2013;14(12):1165–74.
24. Ellen N, Newbould J, Conklin A. International variation in the usage of medicines: a review of the literature. Santa Monica, CA: RAND Corporation. 2010. Available from: http://www.rand.org/pubs/technical_reports/TR830.html.